NZ522279A - Glycopeptide phosphonate derivatives - Google Patents

Glycopeptide phosphonate derivatives

Info

Publication number
NZ522279A
NZ522279A NZ522279A NZ52227901A NZ522279A NZ 522279 A NZ522279 A NZ 522279A NZ 522279 A NZ522279 A NZ 522279A NZ 52227901 A NZ52227901 A NZ 52227901A NZ 522279 A NZ522279 A NZ 522279A
Authority
NZ
New Zealand
Prior art keywords
substituted
glycopeptide
group
alkyl
hydrogen
Prior art date
Application number
NZ522279A
Other languages
English (en)
Inventor
Michael R Leadbetter
Martin S Linsell
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of NZ522279A publication Critical patent/NZ522279A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
NZ522279A 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives NZ522279A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
PCT/US2001/013998 WO2001098328A2 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Publications (1)

Publication Number Publication Date
NZ522279A true NZ522279A (en) 2004-07-30

Family

ID=22795013

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ522279A NZ522279A (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Country Status (36)

Country Link
US (10) US6635618B2 (US07008923-20060307-C00006.png)
EP (1) EP1292612B1 (US07008923-20060307-C00006.png)
JP (2) JP3900491B2 (US07008923-20060307-C00006.png)
KR (1) KR100768488B1 (US07008923-20060307-C00006.png)
CN (1) CN100469788C (US07008923-20060307-C00006.png)
AR (1) AR035333A1 (US07008923-20060307-C00006.png)
AT (1) ATE337334T1 (US07008923-20060307-C00006.png)
AU (2) AU6110701A (US07008923-20060307-C00006.png)
BR (1) BRPI0111222B8 (US07008923-20060307-C00006.png)
CA (2) CA2411590C (US07008923-20060307-C00006.png)
CY (2) CY1105194T1 (US07008923-20060307-C00006.png)
CZ (1) CZ303672B6 (US07008923-20060307-C00006.png)
DE (2) DE60122516T2 (US07008923-20060307-C00006.png)
DK (1) DK1292612T3 (US07008923-20060307-C00006.png)
EA (1) EA005953B1 (US07008923-20060307-C00006.png)
EG (1) EG26726A (US07008923-20060307-C00006.png)
ES (1) ES2271012T3 (US07008923-20060307-C00006.png)
HK (1) HK1052191B (US07008923-20060307-C00006.png)
HR (1) HRP20020888B1 (US07008923-20060307-C00006.png)
HU (2) HU229370B1 (US07008923-20060307-C00006.png)
IL (1) IL152408A (US07008923-20060307-C00006.png)
IS (1) IS2303B (US07008923-20060307-C00006.png)
LU (1) LU91908I2 (US07008923-20060307-C00006.png)
MX (1) MXPA02012745A (US07008923-20060307-C00006.png)
MY (1) MY127081A (US07008923-20060307-C00006.png)
NO (2) NO330360B1 (US07008923-20060307-C00006.png)
NZ (1) NZ522279A (US07008923-20060307-C00006.png)
PL (1) PL207101B1 (US07008923-20060307-C00006.png)
PT (1) PT1292612E (US07008923-20060307-C00006.png)
RS (1) RS50499B (US07008923-20060307-C00006.png)
SI (1) SI1292612T1 (US07008923-20060307-C00006.png)
SK (1) SK287470B6 (US07008923-20060307-C00006.png)
TW (1) TWI305209B (US07008923-20060307-C00006.png)
UA (1) UA75083C2 (US07008923-20060307-C00006.png)
WO (1) WO2001098328A2 (US07008923-20060307-C00006.png)
ZA (1) ZA200209419B (US07008923-20060307-C00006.png)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230190B1 (hu) * 1998-12-23 2015-09-28 Theravance, Inc Glikopeptidszármazékok és ezeket tartalmazó gyógyászati kompozíciók
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
ATE416791T1 (de) 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
AU2001259303A1 (en) 2000-06-22 2002-01-02 Advanced Medicine, Inc. Glycopeptide carboxy-saccharide derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
ES2384707T3 (es) 2002-05-24 2012-07-11 Theravance, Inc. Antibióticos entrecruzados de glucopéptidos y cefalosporinas
US6951963B2 (en) 2002-06-17 2005-10-04 Theravance, Inc. Process for preparing N-protected β-amino aldehyde compounds
US7521418B2 (en) * 2003-05-27 2009-04-21 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
JP4664912B2 (ja) * 2003-07-22 2011-04-06 セラヴァンス， インコーポレーテッド グリコペプチド抗菌剤と組み合わせたエキノカンジン抗真菌剤の使用
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
AU2007204755A1 (en) * 2006-01-10 2007-07-19 Eugene J. Van Scott N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
JP2008112847A (ja) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池
AU2007336674A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
US8741966B2 (en) 2007-11-09 2014-06-03 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
JP2011507959A (ja) * 2007-12-26 2011-03-10 レアド トヘラペウトイクス，インコーポレーテッド 抗菌薬としての新規半合成糖ペプチド
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US20100105607A1 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
PT2424559T (pt) 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
TWI558395B (zh) 2009-05-08 2016-11-21 普諾華生物製藥諾治股份有限公司 新穎的脂質化合物
WO2011005959A1 (en) 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
EA028535B1 (ru) 2010-11-05 2017-11-30 Пронова Биофарма Норге Ас Способы лечения с применением липидных соединений
EP2753637A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin
EP2753638A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
JP5724937B2 (ja) * 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN103897040B (zh) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
EP3578170A1 (en) 2013-02-28 2019-12-11 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
JP2018505910A (ja) 2015-02-23 2018-03-01 セラヴァンス バイオファーマ アンチバイオティクス アイピー， エルエルシー テラバンシンを投与するための用量および方法
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
CN106188243B (zh) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 一种奥利万星的制备方法
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
WO2017194385A1 (en) 2016-05-09 2017-11-16 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
JP7165146B2 (ja) 2017-05-22 2022-11-02 インスメッド インコーポレイテッド グリコペプチド誘導体化合物およびそれらの使用
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
CA3084728A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN108409837B (zh) 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
US20220024980A1 (en) * 2018-11-21 2022-01-27 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IL96603A (en) * 1989-12-13 1998-02-08 Lilly Co Eli Antibacterial glycopeptide derivativesProcess for their preparation and pharmaceutical preparations containing the same
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
AU672862B2 (en) 1992-12-02 1996-10-17 Insite Vision Incorporated Cyclodextrin and polymer based drug delivery system
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
PE40996A1 (es) 1994-01-28 1996-10-14 Lilly Co Eli Derivado de antibiotico de glucopeptido
US5614615A (en) * 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
WO1999017793A1 (fr) * 1997-10-03 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. Chlorhydrates de vancomycines antibiotiques et leur procede de production
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
WO2000004044A1 (en) * 1998-07-14 2000-01-27 Princeton University Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
HU230190B1 (hu) * 1998-12-23 2015-09-28 Theravance, Inc Glikopeptidszármazékok és ezeket tartalmazó gyógyászati kompozíciók
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
WO2000059528A1 (en) 1999-04-02 2000-10-12 The Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
JP2000302687A (ja) 1999-04-22 2000-10-31 Sagami Chem Res Center 抗菌性オリゴマー及び抗菌剤
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
ATE416791T1 (de) 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
UA82824C2 (uk) 2000-06-21 2008-05-26 К'Юбіст Фармасьютікалз, Інк. Композиція і спосіб поліпшення перорального всмоктування протимікробних засобів
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
AU2001259302A1 (en) 2000-06-22 2002-01-02 Yongqi Mu Glycopeptide disulfide and thioester derivatives
AU2001259303A1 (en) 2000-06-22 2002-01-02 Advanced Medicine, Inc. Glycopeptide carboxy-saccharide derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives

Also Published As

Publication number Publication date
CN100469788C (zh) 2009-03-18
NO330360B1 (no) 2011-04-04
DE122011100062I1 (de) 2012-03-15
NO20025954D0 (no) 2002-12-11
US20040063916A1 (en) 2004-04-01
AR035333A1 (es) 2004-05-12
US7008923B2 (en) 2006-03-07
US20100160211A1 (en) 2010-06-24
SK287470B6 (sk) 2010-10-07
US20080312407A1 (en) 2008-12-18
EP1292612A2 (en) 2003-03-19
EP1292612B1 (en) 2006-08-23
DK1292612T3 (da) 2007-01-02
US7700550B2 (en) 2010-04-20
WO2001098328A3 (en) 2002-04-11
YU96902A (sh) 2006-01-16
EA200300050A1 (ru) 2003-04-24
EG26726A (en) 2014-06-18
TWI305209B (en) 2009-01-11
EA005953B1 (ru) 2005-08-25
CY1105194T1 (el) 2010-03-03
HU229370B1 (hu) 2013-11-28
ES2271012T3 (es) 2007-04-16
IS2303B (is) 2007-10-15
US20120283195A1 (en) 2012-11-08
UA75083C2 (uk) 2006-03-15
MXPA02012745A (es) 2004-04-05
BR0111222A (pt) 2003-04-01
US6872701B2 (en) 2005-03-29
SI1292612T1 (sl) 2006-12-31
CY2012006I1 (el) 2016-06-22
KR20030032970A (ko) 2003-04-26
JP3900491B2 (ja) 2007-04-04
US8101575B2 (en) 2012-01-24
LU91908I2 (fr) 2012-01-30
HUS1400024I1 (hu) 2017-03-28
US20050164916A1 (en) 2005-07-28
US20020022590A1 (en) 2002-02-21
US8859506B2 (en) 2014-10-14
JP2004501161A (ja) 2004-01-15
RS50499B (sr) 2010-03-02
DE60122516T2 (de) 2007-01-04
NO20025954L (no) 2002-12-11
CA2411590C (en) 2010-10-19
CA2411590A1 (en) 2001-12-27
US7208471B2 (en) 2007-04-24
AU2001261107B2 (en) 2006-07-20
US20030207797A1 (en) 2003-11-06
BRPI0111222B8 (pt) 2021-05-25
US6887976B2 (en) 2005-05-03
ATE337334T1 (de) 2006-09-15
MY127081A (en) 2006-11-30
PL359419A1 (en) 2004-08-23
IS6600A (is) 2002-10-29
HRP20020888B1 (en) 2007-12-31
PT1292612E (pt) 2006-12-29
PL207101B1 (pl) 2010-11-30
CN1437611A (zh) 2003-08-20
WO2001098328A2 (en) 2001-12-27
HK1052191A1 (en) 2003-09-05
US6635618B2 (en) 2003-10-21
US8541375B2 (en) 2013-09-24
BRPI0111222B1 (pt) 2015-03-17
US7351691B2 (en) 2008-04-01
HRP20020888A2 (en) 2005-02-28
AU6110701A (en) 2002-01-02
DE60122516D1 (de) 2006-10-05
CY2012006I2 (el) 2016-06-22
ZA200209419B (en) 2004-02-19
HUP0301320A3 (en) 2007-05-29
CZ20023942A3 (cs) 2003-03-12
NO2011025I2 (US07008923-20060307-C00006.png) 2011-11-18
CA2713965A1 (en) 2001-12-27
IL152408A0 (en) 2003-05-29
HUP0301320A2 (hu) 2003-08-28
CZ303672B6 (cs) 2013-02-20
US20060063706A1 (en) 2006-03-23
US20140024604A1 (en) 2014-01-23
US20070049519A1 (en) 2007-03-01
SK18522002A3 (sk) 2003-06-03
JP2007045842A (ja) 2007-02-22
IL152408A (en) 2009-05-04
NO2011025I1 (no) 2011-11-18
HK1052191B (zh) 2007-01-26
KR100768488B1 (ko) 2007-10-18

Similar Documents

Publication Publication Date Title
CA2411590C (en) Glycopeptide phosphonate derivatives
US7265086B2 (en) Glycopeptide carboxy-saccharide derivatives
US7244705B2 (en) Polyacid glycopeptide derivatives
AU2001261107A1 (en) Glycopeptide phosphonate derivatives
CA2726789A1 (en) Cyclodextrin containing glycopeptide antibiotic compositions
WO2001098329A1 (en) Polyhydroxy glycopeptide derivatives
WO2001098326A2 (en) Glycopeptide disulfide and thioester derivatives
US6872804B2 (en) Glycopeptide disulfide and thioester derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 01 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20140528

ASS Change of ownership

Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC, US

Effective date: 20140807

ASS Change of ownership

Owner name: CUMBERLAND PHARMACEUTICALS INC., US

Effective date: 20190320

EXPY Patent expired